DBV Technologies SA priced a global offering to raise $125 million, just days after it announced the U.S. Food and Drug Administration accepted its application for peanut allergy therapy Viaskin Peanut.
The French company is looking to sell 9,484,066 ordinary shares made up of 7,914,622 stock that will be sold to investors in the U.S., Canada and certain countries outside of Europe at $6.59 apiece, and 1,569,444 for interested buyers in Europe at €12.04 each.
Goldman Sachs, Citigroup, JMP Securities, H.C. Wainwright & Co. and Bryan Garnier & Co. are overseeing the offering. The underwriters can buy up to an additional 1,368,667 shares from the company.
The company expects the offering to close Oct. 11, raising funds for the commercialization of its peanut allergy therapy Viaskin Peanut.
